presentation by Sanna Turunen, Product Manager, D.Sc. (Tech.), 3DTech Ltd. / Brinter Ltd.
Chondral lesions constitute one of the major extrinsic risk factors for Osteoarthritis (OA), leading to significant societal and economic burden. OA is a highly prevalent condition that can result in disabling pain and loss of physical function.
Horizon 2020 project RESTORE aims to develop and validate nanoenabled solutions in pre-clinical animal models for personalised cartilage regeneration. Different strategies are undertaken to overcome the current challenges and unmet clinical necessities in order to design the most efficient solution towards cartilage repair. RESTORE is building tailored nanocarriers based on polymeric nanobiomaterials, designed to modulate undesirable biological events (inflammation, proteolytic degradation, and bacterial infection), and remotely stimuli-responsive nanobiomaterials to enhance cartilage repair.
Smart 3D matrices for mild and severe chondral lesions are created by integrating nanobiomaterials in COPLA® Scaffold (severe lesions) already present in the animal health market and bioink used for bioprinting of personalised microtissues.
RESTORE is improving cartilage bioprintability by optimising the bioink for human cartilage regeneration and facilitating the development of 3D bioprinter technology by implementing novel printing modalities into bioprinting platform.
What drives you?
My passion is interdisciplinary research at the interface of materials science and health technologies and the curiosity towards novel technological solutions drives me forward.
Why should the delegate attend your presentation?
My presentation will give an overview of the ongoing RESTORE project, which combines several strategies and technological approaches, including 3D bioprinting, to tackle the challenges of cartilage regeneration.
What emerging technologies/trends do you see as having the greatest potential in the short and long run?
Microfluidic bioprinting will probably be one of the potential technologies gaining more attention in the short and long run. Also the combination of several different bioprinting technologies, such as extrusion-based bioprinting together with laser-based fabrication methods will probably be one of the near future approaches to solving the problems related to the achievable resolution with bioprinting.
What kind of impact do you expect them to have?
Combination of several technologies in a single platform will improve the resemblance of the printed structures to natural tissues as more precise details can be mimicked.
What are the barriers that might stand in the way?
The usage of several technologies during a single print job probably requires development from the bioinks as well as they probably need to facilitate the fabrication by being dual crosslinkable via various crosslinking techniques to allow the formation of microstructures inside a macroscopic scaffold.
Anyone who has never made a mistake has never tried anything new. -Albert Einstein
D.Sc. (Tech.) Sanna Turunen works as a product manager of the bioprinting business at 3DTech Ltd./Brinter Ltd. She earned her M.Sc. (Tech.) degree in materials engineering in 2007 from the Tampere University of Technology (TUT), Finland. After graduation, she continued to work as a doctoral student in the Biomaterials and Tissue Engineering Group at TUT. Her research focussed on the fabrication of microstructure-based in vitro cell culture platforms with a laser-based 3D printing technique. She received her D.Sc. (Tech.) in biomedical sciences and engineering in 2017 from TUT. Her main research interests are biomaterials and additive manufacturing technologies for tissue engineering applications.
Brinter is the bioprinting branch of a Finnish 3D printing company, 3DTech Ltd and it will be splitting from the 3DTech Ltd. to form a separate company, Brinter Ltd., on the 1st of January 2021. We provide comprehensive 3D bioprinting solutions and services for pharmaceutical, biotechnological and cosmetic industries, universities, and research facilities. Brinter® bioprinters are always custom-built for clients’ specific applications and needs.
3D Bioprinting Conference focuses on 3D bioprinting, the most disruptive application of 3D printing in the medical world, and latest developments and applications in the field. The conference is addressed to health care innovators, from tissue engineers to biomedical researchers and from hardware manufacturers to bio medical material suppliers. It is not a purely academic conference, but an innovative event bringing together brilliant minds and discoveries.